Table 1 Study subject characteristics... | American Society of Hematology

Table 1

Study subject characteristics

Patient/donor	Age, y	Sex	Source; % blasts	Disease*	Status	Cytogenetics
AML1	79	M	LP; 87%	AML-M1	Untreated	+8
AML2	61	M	PB; 66%	AML-M2	Relapse	+14; FLT3+ (ITD)
AML3	73	F	PB; 64%	AML-M5	Refractory	−5,−12
AML4	53	M	LP; 96%	AML-M5	Untreated	+8; t(9;11)
AML5	24	M	LP; 85%	AML-M1	Untreated	FLT3+ (ITD)
AML6^A2−	41	F	PB; 98%	AML-M1	Untreated	Diploid
AML7†	38	M	PB; 65%	AML-M7	Refractory	−1,−5,−7,−9,−21
AML8	81	F	PB; 92%	AML-M1	Untreated	Diploid
AML9	64	F	PB; 70%	AML-M1	Untreated	Diploid
ALL1‡	65	F	BM; 78%	B-ALL	Untreated	−2,−3,−4,−7,−9
ND1	34	M	PB	NA	NA	NA
ND2	42	F	PB	NA	NA	NA
ND3	35	F	PB	NA	NA	NA
ND4	38	M	PB	NA	NA	NA
ND5	32	M	BM	NA	NA	NA
ND6	53	M	BM	NA	NA	NA
ND7	26	M	BM	NA	NA	NA
ND8	30	M	BM	NA	NA	NA
ND9	58	F	BM	NA	NA	NA
ND10	31	M	BM	NA	NA	NA

Patient/donor	Age, y	Sex	Source; % blasts	Disease*	Status	Cytogenetics
AML1	79	M	LP; 87%	AML-M1	Untreated	+8
AML2	61	M	PB; 66%	AML-M2	Relapse	+14; FLT3+ (ITD)
AML3	73	F	PB; 64%	AML-M5	Refractory	−5,−12
AML4	53	M	LP; 96%	AML-M5	Untreated	+8; t(9;11)
AML5	24	M	LP; 85%	AML-M1	Untreated	FLT3+ (ITD)
AML6^A2−	41	F	PB; 98%	AML-M1	Untreated	Diploid
AML7†	38	M	PB; 65%	AML-M7	Refractory	−1,−5,−7,−9,−21
AML8	81	F	PB; 92%	AML-M1	Untreated	Diploid
AML9	64	F	PB; 70%	AML-M1	Untreated	Diploid
ALL1‡	65	F	BM; 78%	B-ALL	Untreated	−2,−3,−4,−7,−9
ND1	34	M	PB	NA	NA	NA
ND2	42	F	PB	NA	NA	NA
ND3	35	F	PB	NA	NA	NA
ND4	38	M	PB	NA	NA	NA
ND5	32	M	BM	NA	NA	NA
ND6	53	M	BM	NA	NA	NA
ND7	26	M	BM	NA	NA	NA
ND8	30	M	BM	NA	NA	NA
ND9	58	F	BM	NA	NA	NA
ND10	31	M	BM	NA	NA	NA

A2− superscript indicates HLA-A2–negative; LP, leukapheresis collection; PB, peripheral blood; BM, bone marrow; ND, normal donor; and NA, not applicable.

FAB subtype.

†

Antecedent myelodysplastic syndrome.

‡

Ph-chromosome–negative.

View Large

This Feature Is Available To Subscribers Only